Trial Profile
A multicentre, open-label, randomised trial to evaluate the tolerability and mechanism of action of IPH 1101 in antiviral-naive patients with chronic viral hepatitis C infections.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2012
Price :
$35
*
At a glance
- Drugs IPH 1101 (Primary) ; Interleukin-2
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Innate Pharma
- 07 Jul 2012 Inclusion and exclusion criteria amended from EudraCT.
- 03 Jul 2012 Actual Initiation Date (19 Jun 2007) added as reported by European Clinical Trials Database
- 02 Nov 2009 Results presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.